COST-EFFECTIVENESS AND COST-UTILITY OF GENOTHERAPEUTIC DRUG NEOVASCULGEN IN TREATMENT OF CHRONIC LOWER LIMB ISCHEMIA
Pl-VEGF165 (Neovasculgen) is a new genotherapeutic drug for treatment of chronic lower limb ischemia. It is registered in Russia and underwent effectiveness assessment in clinical trial. Objective of this study is to report results of the economical modeling study to compare long-term effectiveness...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2017-11-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2179 |